Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Advertisement

Related Content

CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years
Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova
Newron Overcomes 2011 Disappointments, Moves To Boost CNS Pipeline With NeuroNova Acquisition
Deals of the Week: GSK Working On Three Deals, Agilent/Dako
Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses
Diversification Fails To Protect Merck KGaA From Industry Pressures
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Germany's Merck Scraps MS Drug Cladribine After Regulators' Rebuff
Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS072921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel